Chlorpromazine, Serum or Plasma
Use
Chlorpromazine is a neuroleptic drug used to treat schizophrenia, psychotic disorders, and intractable hiccup. Monitoring chlorpromazine levels helps in optimizing drug therapy and ensuring patient adherence. Chlorpromazine is not recommended for patients with epilepsy, Parkinson's disease, hypoparathyroidism, myasthenia gravis, and prostatic hypertrophy due to possible adverse effects, including drowsiness, hypotension, agranulocytosis, cardiac abnormalities, seizures, and rare life-threatening conditions such as phenothiazine sudden death syndrome and neuroleptic malignant syndrome.
Special Instructions
Not provided.
Limitations
This test was developed by ARUP Laboratories and its performance characteristics determined by them. It has not been cleared or approved by the US Food and Drug Administration. The test should be performed in a CLIA certified laboratory and is intended for clinical purposes. Chlorpromazine in whole blood, hemolyzed specimens, and certain tube types (gel separator, light blue citrate, yellow SPS or ACD) is unacceptable.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
Chlorpromazine
Analyte
LOINC Codes
- 3471-0 - chlorproMAZINE SerPl-mCnc
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum or plasma from cells within 2 hours of collection.
Patient Preparation
Predose (trough) draw at steady state concentration.
Causes for Rejection
Whole blood, hemolyzed specimens, gel separator tubes, light blue (citrate) or yellow (SPS or ACD solution).
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant